Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ECI830 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on ECI830 (Apr 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ECI830 | ECI-830|ECI 830 | Limited information is currently available on ECI830 (Apr 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06726148 | Phase Ib/II | ECI830 + Fulvestrant + Ribociclib ECI830 Fulvestrant + Ribociclib ECI830 + Fulvestrant | Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | Recruiting | USA | ITA | ISR | FRA | DNK | DEU | CZE | CAN | AUS | 4 |